文摘
目的:描述院前治疗和结果之间的关系在儿童难治性癫痫癫痫持续状态(交易所)。方法:多中心前瞻性观察性队列研究包括儿科患者的比例,承认从2011年到2015年,他失败了至少两个抗癫痫药物。结果:患者队列由184 (p25-p75)年龄中位数为4.3(1.4 - -9.7)年。122患者心脏按压证交所发病和62年住院交易所开始。之前的诊断癫痫和SE是出现在87年(47 [percnt])和34 (18 [percnt])患者,分别。时间先苯二氮(BZD)剂量为19.5(5-55)分钟,长在那些心脏发病(30(7.5 -65)分钟)相比,发病住院[10(5-29)分钟](p < 0.001)。时间第一次non-BZD政府65年(35 - 161)分钟,心脏按压患者发病的时间较长(83(45.5 - -175.5)分钟)相比,发病住院(46(25 - 93)分钟)(p < 0.001)。患者心脏按压SE开始在家收到了第一个BZD [29 (24 [percnt])],在救护车(34 (28 [percnt])),或在医院(58 (48 (percnt)))。病人院前治疗更快管理第一BZD (p < 0.01,系数5.5 - 122.6分钟)和倍在时间表之前接受第一个BZD建议(10分钟)(p < 0.01)。控制病因、年龄和发热,病人院前治疗更有可能ICU停留较短(p < 0.05,系数- 6.8天),要求缩短插管时间(p < 0.01,系数- 164.4小时),减少了时间来恢复意识(p < 0.01,系数- 93.1小时),回到基线函数在放电时间(p < 0.01, O。3.9 R),减少相关并发症(p < 0.05, O。0.3 R)。 Mortality, need for intubation, EEG duration, SE duration, and hypotension were not associated with pre-hospital treatment. Conclusions: Pre-hospital treatment was associated with shorter ICU duration, shorter intubation, reduced time to regain consciousness, higher return-to-baseline function, fewer medical complications, and higher achievement of treatment recommended timeframes. SE patients may benefit from a home rescue medication plan and improved EMS protocols to meet recommended treatment timeframes and achieve better outcomes.
披露:博士Gainza Lein没有披露。桑切斯博士费尔南德斯已经收到了研究支持Fundacion阿方索马丁Escudero和HHV6基金会。杰克逊博士没有披露。异常终止博士已经收到个人赔偿与演示活动。异常终止博士已经收到NIH的研究支持,小儿癫痫研究基金会、美国癫痫协会,辉瑞。Arya博士没有披露。Brenton博士没有披露。博士木匠没有披露。查普曼博士没有披露。盖拉德博士已经收到了来自美国国立卫生研究院和研究支持美国癫痫的基础。 Dr. Glauser has received (royalty or license fee or contractual rights) payments from AssureRx Health. Dr. Goldstein has nothing to disclose. Dr. Goodkin has received personal compensation in an editorial capacity for Up-To-Date. Dr. Helseth has nothing to disclose. Dr. Kapur has nothing to disclose. Dr. Mikati has nothing to disclose. Dr. Peariso has nothing to disclose. Dr. Tasker has nothing to disclose. Dr. Topjian has nothing to disclose. Dr. Wainwright has received personal compensation for activities with Sage Therapeutics. Dr. Wilfong has received research support from Novartis, Pfizer, UCB, Upsher-Smith, Lundbeck, GW Pharma, and Eisai. Dr. Williams has nothing to disclose. Dr. Loddenkemper has received personal compensation for serving on the board for the Laboratory Accreditation Board for Long Term Monitoring, the American Clinical Neurophysiology Society, Clinical Neurophysiology, and Upsher Smith. Dr. Loddenkemper has r
周二,2016年4月19日,8:30 am-7:00点
- 版权©2016年长企业公司,。
